10
Participants
Start Date
January 31, 2014
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
Thalidomide
100 mg by mouth daily for 28 days in a 28 day cycle.
Lenalidomide
Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
Questionnaires
Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Celgene Corporation
INDUSTRY
M.D. Anderson Cancer Center
OTHER